Furthermore, we established BCR-ABL stable transfectant and control empty vector transfectant from TF-1, a factor-dependent human erythroleukemia cell line, to verify our results obtained with CML cell lines.
Selective inhibition of the proliferation in K562 cells was greatly enhanced by combined treatment with acycloguanosine and herbimycin A, while the growth of another erythroleukemia cell line without bcr/abl gene (HEL) and normal mouse bone marrow cells was hardly affected by the treatment.